Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00823212




Registration number
NCT00823212
Ethics application status
Date submitted
13/01/2009
Date registered
13/01/2009
Date last updated
13/03/2019

Titles & IDs
Public title
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
Scientific title
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions
Secondary ID [1] 0 0
ACTRN12608000582358
Secondary ID [2] 0 0
S2046
Universal Trial Number (UTN)
Trial acronym
PLATINUM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease 0 0
Coronary Artery Disease 0 0
Coronary Artery Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - PROMUS Coronary Stent System
Treatment: Devices - PROMUS Element Coronary Stent System
Treatment: Drugs - Aspirin
Treatment: Drugs - Thienopyridine
Treatment: Devices - PROMUS Coronary Stent System
Treatment: Devices - PROMUS Element Coronary Stent System
Treatment: Drugs - Aspirin
Treatment: Drugs - Thienopyridine
Treatment: Devices - PROMUS Coronary Stent System
Treatment: Devices - PROMUS Element Coronary Stent System
Treatment: Drugs - Aspirin
Treatment: Drugs - Thienopyridine

Active Comparator: PROMUS - Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent

Experimental: PROMUS Element - Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent

Active Comparator: PROMUS - Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent

Experimental: PROMUS Element - Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent

Active Comparator: PROMUS - Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent

Experimental: PROMUS Element - Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent


Treatment: Devices: PROMUS Coronary Stent System
PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

Treatment: Devices: PROMUS Element Coronary Stent System
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).

Treatment: Drugs: Aspirin
Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

Treatment: Drugs: Thienopyridine
Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.

Treatment: Devices: PROMUS Coronary Stent System
PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

Treatment: Devices: PROMUS Element Coronary Stent System
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).

Treatment: Drugs: Aspirin
Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

Treatment: Drugs: Thienopyridine
Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.

Treatment: Devices: PROMUS Coronary Stent System
PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

Treatment: Devices: PROMUS Element Coronary Stent System
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).

Treatment: Drugs: Aspirin
Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

Treatment: Drugs: Thienopyridine
Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.

Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Target Lesion Failure (TLF) - Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [1] 0 0
12-month post index procedure
Primary outcome [2] 0 0
Target Lesion Failure (TLF) - Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [2] 0 0
12-month post index procedure
Primary outcome [3] 0 0
Target Lesion Failure (TLF) - Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [3] 0 0
12-month post index procedure
Secondary outcome [1] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [1] 0 0
30 days
Secondary outcome [2] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [2] 0 0
6 months
Secondary outcome [3] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [3] 0 0
12 months
Secondary outcome [4] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [4] 0 0
30 days
Secondary outcome [5] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [5] 0 0
6 months
Secondary outcome [6] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [6] 0 0
12 months
Secondary outcome [7] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [7] 0 0
30 days
Secondary outcome [8] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [8] 0 0
6 months
Secondary outcome [9] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [9] 0 0
12 months
Secondary outcome [10] 0 0
All Cause Mortality
Timepoint [10] 0 0
30 days
Secondary outcome [11] 0 0
All Cause Mortality
Timepoint [11] 0 0
6 months
Secondary outcome [12] 0 0
All Cause Mortality
Timepoint [12] 0 0
12 months
Secondary outcome [13] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [13] 0 0
30 days
Secondary outcome [14] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [14] 0 0
6 months
Secondary outcome [15] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [15] 0 0
12 months
Secondary outcome [16] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [16] 0 0
30 Days
Secondary outcome [17] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [17] 0 0
6 Months
Secondary outcome [18] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [18] 0 0
12 months
Secondary outcome [19] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [19] 0 0
30 days
Secondary outcome [20] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [20] 0 0
6 months
Secondary outcome [21] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [21] 0 0
12 months
Secondary outcome [22] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [22] 0 0
30 days
Secondary outcome [23] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [23] 0 0
6 months
Secondary outcome [24] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [24] 0 0
12 months
Secondary outcome [25] 0 0
Target Lesion Revascularization (TLR) - Target lesion revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [25] 0 0
30 days
Secondary outcome [26] 0 0
Target Lesion Revascularization (TLR) - TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [26] 0 0
6 months
Secondary outcome [27] 0 0
Target Lesion Revascularization (TLR) - TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [27] 0 0
12 months
Secondary outcome [28] 0 0
Target Vessel Revascularization (TVR) - Target vessel revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [28] 0 0
30 days
Secondary outcome [29] 0 0
Target Vessel Revascularization (TVR) - TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [29] 0 0
6 months
Secondary outcome [30] 0 0
Target Vessel Revascularization (TVR) - TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [30] 0 0
12 months
Secondary outcome [31] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [31] 0 0
24 hours
Secondary outcome [32] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [32] 0 0
>24 hr-30 days
Secondary outcome [33] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [33] 0 0
>30 days-1 year
Secondary outcome [34] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR
Timepoint [34] 0 0
30 days
Secondary outcome [35] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR.
Timepoint [35] 0 0
6 months
Secondary outcome [36] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR.
Timepoint [36] 0 0
12 months
Secondary outcome [37] 0 0
Clinical Procedural Success - Defined as mean lesion diameter stenosis <30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or cardiac death
Timepoint [37] 0 0
In hospital
Secondary outcome [38] 0 0
Acute Technical Success - Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent
Timepoint [38] 0 0
Acute-At time of index procedure
Secondary outcome [39] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [39] 0 0
30 days
Secondary outcome [40] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [40] 0 0
6 months
Secondary outcome [41] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [41] 0 0
12 months
Secondary outcome [42] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [42] 0 0
30 days
Secondary outcome [43] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [43] 0 0
6 months
Secondary outcome [44] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [44] 0 0
12 months
Secondary outcome [45] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [45] 0 0
30 days
Secondary outcome [46] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [46] 0 0
6 months
Secondary outcome [47] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [47] 0 0
12 months
Secondary outcome [48] 0 0
All Cause Mortality
Timepoint [48] 0 0
30 days
Secondary outcome [49] 0 0
All Cause Mortality
Timepoint [49] 0 0
6 months
Secondary outcome [50] 0 0
All Cause Mortality
Timepoint [50] 0 0
12 months
Secondary outcome [51] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [51] 0 0
30 days
Secondary outcome [52] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [52] 0 0
6 months
Secondary outcome [53] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [53] 0 0
12 months
Secondary outcome [54] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [54] 0 0
30 Days
Secondary outcome [55] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [55] 0 0
6 Months
Secondary outcome [56] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [56] 0 0
12 months
Secondary outcome [57] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [57] 0 0
30 days
Secondary outcome [58] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [58] 0 0
6 months
Secondary outcome [59] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [59] 0 0
12 months
Secondary outcome [60] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [60] 0 0
30 days
Secondary outcome [61] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [61] 0 0
6 months
Secondary outcome [62] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [62] 0 0
12 months
Secondary outcome [63] 0 0
Target Lesion Revascularization (TLR) - Target lesion revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [63] 0 0
30 days
Secondary outcome [64] 0 0
Target Lesion Revascularization (TLR) - TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [64] 0 0
6 months
Secondary outcome [65] 0 0
Target Lesion Revascularization (TLR) - TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [65] 0 0
12 months
Secondary outcome [66] 0 0
Target Vessel Revascularization (TVR) - Target vessel revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [66] 0 0
30 days
Secondary outcome [67] 0 0
Target Vessel Revascularization (TVR) - TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [67] 0 0
6 months
Secondary outcome [68] 0 0
Target Vessel Revascularization (TVR) - TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [68] 0 0
12 months
Secondary outcome [69] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [69] 0 0
24 hours
Secondary outcome [70] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [70] 0 0
>24 hr-30 days
Secondary outcome [71] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [71] 0 0
>30 days-1 year
Secondary outcome [72] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR
Timepoint [72] 0 0
30 days
Secondary outcome [73] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR.
Timepoint [73] 0 0
6 months
Secondary outcome [74] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR.
Timepoint [74] 0 0
12 months
Secondary outcome [75] 0 0
Clinical Procedural Success - Defined as mean lesion diameter stenosis <30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or cardiac death
Timepoint [75] 0 0
In hospital
Secondary outcome [76] 0 0
Acute Technical Success - Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent
Timepoint [76] 0 0
Acute-At time of index procedure
Secondary outcome [77] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [77] 0 0
30 days
Secondary outcome [78] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [78] 0 0
6 months
Secondary outcome [79] 0 0
Target Lesion Failure (TLF) - TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Timepoint [79] 0 0
12 months
Secondary outcome [80] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [80] 0 0
30 days
Secondary outcome [81] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [81] 0 0
6 months
Secondary outcome [82] 0 0
Target Vessel Failure (TVF) - TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Timepoint [82] 0 0
12 months
Secondary outcome [83] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [83] 0 0
30 days
Secondary outcome [84] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [84] 0 0
6 months
Secondary outcome [85] 0 0
Myocardial Infarction (MI) Related to the Target Vessel - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [85] 0 0
12 months
Secondary outcome [86] 0 0
All Cause Mortality
Timepoint [86] 0 0
30 days
Secondary outcome [87] 0 0
All Cause Mortality
Timepoint [87] 0 0
6 months
Secondary outcome [88] 0 0
All Cause Mortality
Timepoint [88] 0 0
12 months
Secondary outcome [89] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [89] 0 0
30 days
Secondary outcome [90] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [90] 0 0
6 months
Secondary outcome [91] 0 0
Cardiac Death Related to the Target Vessel - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Timepoint [91] 0 0
12 months
Secondary outcome [92] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [92] 0 0
30 Days
Secondary outcome [93] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [93] 0 0
6 Months
Secondary outcome [94] 0 0
Non-cardiac Death - Defined as a death not due to cardiac causes (see definition of cardiac death above)
Timepoint [94] 0 0
12 months
Secondary outcome [95] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [95] 0 0
30 days
Secondary outcome [96] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [96] 0 0
6 months
Secondary outcome [97] 0 0
Cardiac Death or Myocardial Infarction (MI) - Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Timepoint [97] 0 0
12 months
Secondary outcome [98] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [98] 0 0
30 days
Secondary outcome [99] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [99] 0 0
6 months
Secondary outcome [100] 0 0
All Death or Myocardial Infarction (MI) - Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) >3x normal (peri-percutaneous coronary intervention [PCI]) or >2x normal (spontaneous) with elevated CK-MB, or troponin >3x normal (peri-PCI) or >2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin >5x normal
Timepoint [100] 0 0
12 months
Secondary outcome [101] 0 0
Target Lesion Revascularization (TLR) - Target lesion revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [101] 0 0
30 days
Secondary outcome [102] 0 0
Target Lesion Revascularization (TLR) - TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [102] 0 0
6 months
Secondary outcome [103] 0 0
Target Lesion Revascularization (TLR) - TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Timepoint [103] 0 0
12 months
Secondary outcome [104] 0 0
Target Vessel Revascularization (TVR) - Target vessel revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [104] 0 0
30 days
Secondary outcome [105] 0 0
Target Vessel Revascularization (TVR) - TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [105] 0 0
6 months
Secondary outcome [106] 0 0
Target Vessel Revascularization (TVR) - TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Timepoint [106] 0 0
12 months
Secondary outcome [107] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [107] 0 0
24 hours
Secondary outcome [108] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [108] 0 0
>24 hr-30 days
Secondary outcome [109] 0 0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition - DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Timepoint [109] 0 0
>30 days-1 year
Secondary outcome [110] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR
Timepoint [110] 0 0
30 days
Secondary outcome [111] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR.
Timepoint [111] 0 0
6 months
Secondary outcome [112] 0 0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR) - See above for definitions of MI and TVR.
Timepoint [112] 0 0
12 months
Secondary outcome [113] 0 0
Clinical Procedural Success - Defined as mean lesion diameter stenosis <30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or cardiac death
Timepoint [113] 0 0
In hospital
Secondary outcome [114] 0 0
Acute Technical Success - Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent
Timepoint [114] 0 0
Acute-At time of index procedure

Eligibility
Key inclusion criteria
- Patient must be at least 18 years of age

- Patient (or legal guardian) understands study requirements and treatment procedures
and provides written informed consent before any study-specific tests or procedures
are performed

- For patients less than 20 years of age enrolled at a Japanese site, patient and
patient's legal representative must provide written informed consent before any
study-specific tests or procedures are performed

- Patient is eligible for percutaneous coronary intervention (PCI)

- Patient has documented stable angina pectoris or documented silent ischemia; or
unstable angina pectoris

- Patient is an acceptable candidate for coronary artery bypass grafting (CABG)

- Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30
days prior to enrollment

- Patient is willing to comply with all protocol-required follow-up evaluations

Angiographic Inclusion Criteria (visual estimate):

- Target lesion must be a de novo lesion located in a native coronary artery with a
visually estimated reference vessel diameter (RVD) >=2.50 mm and <=4.25 mm. Target lesion
length must measure (by visual estimate) <=24 mm. Target lesion must be in a major coronary
artery or branch with visually estimated stenosis >=50% and <100% with Thrombolysis in
Myocardial Infarction (TIMI) flow >1.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
acute myocardial infarction (MI)

- Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index
procedure) and has elevated enzymes at time of index procedure as follows.

- Patients are excluded if any of the following criteria are met at time of the
index procedure.

- If creatine kinase-myoglobin band (CK-MB) >2× upper limit of normal (ULN),
the patient is excluded regardless of CK Total.

- If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.

- If CK Total/CK MB are not used and Troponin is, patients are excluded if the
following criterion is met at time of index procedure.

- Troponin >1× ULN with at least one of the following.

- Patient has ischemic symptoms and ECG changes indicative of ongoing
ischemia (eg, >1 mm ST segment elevation or depression in consecutive
leads or new left bundle branch block [LBBB]);

- Development of pathological Q waves in the ECG; or

- Imaging evidence of new loss of viable myocardium or new regional wall
motion abnormality.

Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK
MB (or Troponin if CK Total/CK MB are not used) must be documented prior to
enrolling/randomizing the patient.

- Patient has received an organ transplant or is on a waiting list for an organ
transplant

- Patient is receiving or scheduled to receive chemotherapy within 30 days before or
after index procedure

- Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled
steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune
disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not
including diabetes mellitus)

- Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin,
coumadin) for indications other than acute coronary syndrome

- Patient has platelet count <100,000 cells/mm3 or >700,000 cells/mm3

- Patient has white blood cell (WBC) count <3,000 cells/mm3

- Patient has documented or suspected liver disease, including laboratory evidence of
hepatitis

- Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine
clearance <50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight
(in kg)]/[plasma creatinine (mg/dl)*72])

- Patient has history of bleeding diathesis or coagulopathy or will refuse blood
transfusions

- Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
within past 6 months, or has any permanent neurologic defect that may cause
non-compliance with the protocol

- Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon
angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index
procedure

- Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by
visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting
balloon, atherectomy) at any time prior to index procedure

- Non-target vessel or side branch has been treated with any type of PCI (eg, balloon
angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index
procedure

- Planned or actual target vessel(s) treatment with an unapproved device, directional or
rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction
catheter immediately prior to stent placement

- Planned PCI or CABG after index procedure

- Patient previously treated at any time with coronary intravascular brachytherapy

- Patient has a known allergy to the study stent system or protocol-required concomitant
medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten,
acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot
be adequately premedicated

- Patient has active peptic ulcer or active gastrointestinal (GI) bleeding

- Patient has one of the following.

- Other serious medical illness (eg, cancer, congestive heart failure) that may
reduce life expectancy to less than 24 months

- Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)

- Planned procedure that may cause non-compliance with protocol or confound data
interpretation

- Patient is participating in another investigational drug or device clinical trial that
has not reached its primary endpoint

- Patient intends to participate in another investigational drug or device clinical
trial within 12 months after index procedure

- Patient with known intention to procreate within 12 months after index procedure
(Women of child-bearing potential who are sexually active must agree to use a reliable
method of contraception from the time of screening through 12 months after the index
procedure.)

- Patient is a woman who is pregnant or nursing (A pregnancy test must be performed
within 7 days prior to the index procedure in women of child-bearing potential)

- Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target
lesion, which will be treated during the index procedure

Angiographic Exclusion Criteria (visual estimate):

- Target lesion meets any of the following criteria:

- Aorto-ostial location (ie, lesion located within 5 mm of ostium by visual
estimate)

- Left main location

- Located within 5 mm of origin of the left anterior descending (LAD) coronary
artery or left circumflex (LCX) coronary artery by visual estimate

- Located within a saphenous vein graft or arterial graft

- Will be accessed via a saphenous vein graft or arterial graft

- Involves a side branch >=2.0 mm in diameter by visual estimate

- Involves a clinically significant side branch <2.0 mm in diameter by visual
estimate that has a clinically significant stenosis at the ostium

- TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing

- Excessive tortuosity proximal to or within the lesion

- Extreme angulation proximal to or within the lesion

- Target lesion and/or target vessel proximal to the target lesion is moderately to
severely calcified by visual estimate

- Restenotic from previous intervention

- Thrombus, or possible thrombus, present in target vessel

- Non-target lesion to be treated during the index procedure meets any of the following
criteria:

- Located within the target vessel

- Located within a bypass graft (venous or arterial)

- Left main location

- Chronic total occlusion

- Involves a complex bifurcation (eg, bifurcations requiring treatment with more
than 1 stent)

- Restenotic from previous intervention

- Patient has unprotected left main coronary artery disease (>50% diameter stenosis)

- Patient has protected left main coronary artery disease and a target lesion in the LAD
or LCX

- Patient has an additional clinically significant lesion(s) in target vessel for which
an intervention within 12 months after the index procedure is likely to be required

- Patient has 2 target lesions in the same vessel that are separated by less than 15 mm
(by visual estimate) Note: Multiple focal stenoses will be considered as a single
lesion if they can be completely covered with 1 stent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [2] 0 0
St. Vincent's Hospital - Fitzroy
Recruitment hospital [3] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [4] 0 0
The Prince Charles Hospital - Queensland
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
6000 - Perth
Recruitment postcode(s) [4] 0 0
4032 - Queensland
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maine
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Mississippi
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
Nebraska
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Washington
Country [32] 0 0
United States of America
State/province [32] 0 0
Wisconsin
Country [33] 0 0
Austria
State/province [33] 0 0
Vienna
Country [34] 0 0
Belgium
State/province [34] 0 0
Antwerpen
Country [35] 0 0
Belgium
State/province [35] 0 0
Genk
Country [36] 0 0
Belgium
State/province [36] 0 0
Gent
Country [37] 0 0
Belgium
State/province [37] 0 0
Leuven
Country [38] 0 0
Denmark
State/province [38] 0 0
Aarhus
Country [39] 0 0
Denmark
State/province [39] 0 0
Copenhagen
Country [40] 0 0
Finland
State/province [40] 0 0
Oulu
Country [41] 0 0
Finland
State/province [41] 0 0
Tampere
Country [42] 0 0
Finland
State/province [42] 0 0
Turku
Country [43] 0 0
France
State/province [43] 0 0
Besancon
Country [44] 0 0
France
State/province [44] 0 0
Bordeaux
Country [45] 0 0
France
State/province [45] 0 0
Massy
Country [46] 0 0
France
State/province [46] 0 0
Montpellier
Country [47] 0 0
France
State/province [47] 0 0
Toulouse
Country [48] 0 0
Germany
State/province [48] 0 0
Bad Nauheim
Country [49] 0 0
Germany
State/province [49] 0 0
Bad Oeynhausen
Country [50] 0 0
Germany
State/province [50] 0 0
Bad Segeberg
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Heidelberg
Country [53] 0 0
Germany
State/province [53] 0 0
Leipzig
Country [54] 0 0
Japan
State/province [54] 0 0
Fukuoka
Country [55] 0 0
Japan
State/province [55] 0 0
Hokkaido
Country [56] 0 0
Japan
State/province [56] 0 0
Kanagawa
Country [57] 0 0
Japan
State/province [57] 0 0
Tokyo
Country [58] 0 0
Japan
State/province [58] 0 0
Osaka
Country [59] 0 0
Latvia
State/province [59] 0 0
Riga
Country [60] 0 0
Malaysia
State/province [60] 0 0
Sarawak
Country [61] 0 0
Malaysia
State/province [61] 0 0
Kuala Lumpur
Country [62] 0 0
Netherlands
State/province [62] 0 0
Alkmaar
Country [63] 0 0
Netherlands
State/province [63] 0 0
Breda
Country [64] 0 0
Netherlands
State/province [64] 0 0
Eindhoven
Country [65] 0 0
Netherlands
State/province [65] 0 0
Nieuwegein
Country [66] 0 0
New Zealand
State/province [66] 0 0
Auckland
Country [67] 0 0
New Zealand
State/province [67] 0 0
Wellington
Country [68] 0 0
Poland
State/province [68] 0 0
Bydgoszcz
Country [69] 0 0
Poland
State/province [69] 0 0
Krakow
Country [70] 0 0
Poland
State/province [70] 0 0
Warsaw
Country [71] 0 0
Poland
State/province [71] 0 0
Wroklaw
Country [72] 0 0
Portugal
State/province [72] 0 0
Carnaxide
Country [73] 0 0
Singapore
State/province [73] 0 0
Singapore
Country [74] 0 0
United Kingdom
State/province [74] 0 0
England
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Ireland
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Clydebank
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boston Scientific Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™
Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo
atherosclerotic coronary artery lesions.

This clinical trial compares outcomes in patients treated with PROMUS Element to those in
patients treated with a different everolimus-eluting coronary stent. The lesions are of
average length in average-sized vessels ("workhorse"). A companion sub-trial evaluates
outcomes in smaller vessels (SV) and another sub-trial evaluates outcomes in longer lesions
(LL).
Trial website
https://clinicaltrials.gov/show/NCT00823212
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Peter M Maurer, MPH
Address 0 0
Boston Scientific Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications